Reports outline thalassemia study findings from Cincinnati Children's Hospital

New research, 'Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective,' is the subject of a report. "Gene therapy for beta-globinopathies, particularly Beta-thalassemia and sickle cell anemia, holds promise for the future as a definitive corrective approach for these common and debilitating disorders. Correction of the beta-globinopathies using lentivirus vectors carrying the beta-or y-globin genes and elements of the locus control region has now been well established in murine models, and an understanding of 'what is required to cure these diseases' has been developed in the first decade of the 21st century," scientists in the United States...

Want to see the full article?

• Purchase this article for only $3.00